ArticleNature communications2021

Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.

Jing Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.